Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia

M. MAKRIS,* T. BAGLIN, G. DUSHEIKO,à P. L. F. GIANGRANDE,§ C. A. LEE,à C. A. LUDLAM,± F. E. PRESTON,* H. G. WATSON,** J. T. WILDE and M. WINTERàà ON BEHALF OF THE TRANSFUSION TRANSMITTED INFECTION WORKING PARTY OF THE UK HAEMOPHILIA CENTRE DIRECTORS ORGANIZATION *Shef®eld Haemophilia and Thrombosis Centre, Shef®eld; àRoyal Free Hospital, Department of Medicine and Haemophilia Centre and Haemostasis Unit, London; West Midlands Adult Haemophilia Centre, Birmingham; and the Haemophilia centres of Cambridge; §Oxford; ±Edinburgh; **Aberdeen; and ààCanterbury, UK

[1]  C. Sabin,et al.  The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985 , 2000, Gut.

[2]  R. Pilkington,et al.  Liver biopsy in Irish hepatitis C‐infected patients with inherited bleeding disorders , 2000, British journal of haematology.

[3]  Muir,et al.  Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders , 2000, British journal of haematology.

[4]  E. Jury.  EASL International Consensus Conference on Hepatitis C , 1999, Journal of hepatology.

[5]  J. Bruix,et al.  Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. , 1999, Journal of hepatology.

[6]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[7]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[8]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[9]  N. Hayashi,et al.  GBV‐C/HGV infection in chronic hepatitis C patients: Its effect on clinical features and interferon therapy , 1998, Journal of medical virology.

[10]  M Kundi,et al.  Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). , 1998, Acta tropica.

[11]  C. Sabin,et al.  Outcome of orthotopic liver transplantation in patients with haemophilia , 1998, Gut.

[12]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[13]  T. Ferraro,et al.  Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. , 1998, The New England journal of medicine.

[14]  Aril Frydén,et al.  Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.

[15]  G. Davis,et al.  Factors predictive of a beneficial response to therapy of hepatitis C , 1997, Hepatology.

[16]  S. Darby,et al.  Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C , 1997, The Lancet.

[17]  D. Pillay,et al.  Hepatitis G virus infection in patients with bleeding disorders , 1997, British journal of haematology.

[18]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[19]  S. Lemon.  Type A viral hepatitis: epidemiology, diagnosis, and prevention. , 1997, Clinical chemistry.

[20]  P. Pontisso,et al.  A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. , 1997, Blood.

[21]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[22]  P. Simmonds,et al.  Infection with hepatitis G virus among recipients of plasma products , 1996, The Lancet.

[23]  P. Simmonds,et al.  Hepatitis B serology and DNA detection in multitransfused haemophiliacs and factor VIII and IX concentrates , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  F. Rosendaal,et al.  The natural history of chronic hepatitis C in haemophiliacs , 1996, British journal of haematology.

[25]  G. Calandra,et al.  Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. , 1996, Vaccine.

[26]  C. Chan,et al.  Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters. , 1996, The American journal of gastroenterology.

[27]  C. Sabin,et al.  The progression of HCV‐associated liver disease in a cohort of haemophilic patients , 1994, British journal of haematology.

[28]  P. Mannucci,et al.  The Outbreak of Hepatitis A in Italian Patients with Hemophilia: Facts and Fancies , 1994, Vox sanguinis.

[29]  E. Santagostino,et al.  Accelerated schedule of hepatitis B vaccination in patients with hemophilia , 1993, Journal of medical virology.

[30]  J. Kurtz,et al.  Low risk of sexual transmission of hepatitis C virus , 1993, Journal of medical virology.

[31]  J. Goedert,et al.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.

[32]  P. Simmonds,et al.  Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non‐virus inactivated factor VIII and IX concentrates , 1992, British journal of haematology.

[33]  M. Colombo,et al.  Hepatocellular carcinoma in hemophilia , 1991, American journal of hematology.

[34]  A. Zanetti,et al.  Suboptimal response to hepatitis B vaccine in drug users. , 1991, Archives of internal medicine.

[35]  J. Lau,et al.  Comparison of two plasma‐derived hepatitis B vaccines: Long‐term report of a prospective, randomized trial , 1989, Journal of gastroenterology and hepatology.

[36]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.

[37]  B. Evatt,et al.  Risk of hepatitis A virus infection in persons with hemophilia receiving plasma-derived products. , 2000, Transfusion medicine reviews.

[38]  Willis C. Maddrey,et al.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.

[39]  M. Chang,et al.  Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. , 1998, Vaccine.

[40]  O. Weiland,et al.  Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. , 1998, Lancet.

[41]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[42]  P. Pontisso,et al.  A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. , 1997, Blood.